Physician profile
Devashis Mitra
NPI 1326148289
$636.38
in general payments reported to CMS, 2019-2025
10 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.23 · 2020: $12.60 · 2022: $99.00 · 2024: $71.45 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $116.86 | 2019-2022 | |
| Ucb, INC. | $113.62 | 2025 | Bimzelx |
| Abbvie INC. | $87.49 | 2025 | |
| Exact Sciences Corporation | $71.45 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $58.38 | 2025 | Tymlos |
| Averitas Pharma INC. | $58.37 | 2025 | Qutenza |
| Dexcom, INC. | $55.28 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Pfizer INC. | $28.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.42 | 2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $21.54 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devashis Mitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.